MX2023010418A - Dominio de union al antigeno y polipeptido que incluye seccion de transporte. - Google Patents
Dominio de union al antigeno y polipeptido que incluye seccion de transporte.Info
- Publication number
- MX2023010418A MX2023010418A MX2023010418A MX2023010418A MX2023010418A MX 2023010418 A MX2023010418 A MX 2023010418A MX 2023010418 A MX2023010418 A MX 2023010418A MX 2023010418 A MX2023010418 A MX 2023010418A MX 2023010418 A MX2023010418 A MX 2023010418A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding domain
- domain
- conveying section
- polypeptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 230000027455 binding Effects 0.000 title abstract 7
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
La presente invención se refiere a un polipéptido que comprende un dominio de unión al antígeno y una porción portadora que tiene un dominio de inhibición que inhibe la actividad de unión al antígeno del dominio de unión al antígeno, y que tiene una semivida más prolongada que aquella del dominio de unión al antígeno que existe solo, a métodos para producir y seleccionar el polipéptido, a una composición farmacéutica que comprende el polipéptido, a métodos para producir y seleccionar un anticuerpo de dominio único cuya actividad de unión al antígeno sea inhibida al asociarse con una VL, VH o VHH particular, y a una biblioteca del polipéptido de fusión que incluye un anticuerpo de dominio único cuya actividad de unión al antígeno sea inhibida al asociarse con una VL, VH o VHH particular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016229794 | 2016-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010418A true MX2023010418A (es) | 2023-09-18 |
Family
ID=62195243
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005756A MX2019005756A (es) | 2016-11-28 | 2017-11-28 | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
MX2023010419A MX2023010419A (es) | 2016-11-28 | 2019-05-16 | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
MX2023010418A MX2023010418A (es) | 2016-11-28 | 2019-05-16 | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005756A MX2019005756A (es) | 2016-11-28 | 2017-11-28 | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
MX2023010419A MX2023010419A (es) | 2016-11-28 | 2019-05-16 | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. |
Country Status (13)
Country | Link |
---|---|
US (3) | US11168139B2 (es) |
EP (1) | EP3546574A4 (es) |
JP (3) | JP7001615B2 (es) |
KR (2) | KR102630923B1 (es) |
CN (2) | CN110177875B (es) |
AU (2) | AU2017364817B2 (es) |
BR (1) | BR112019008727A2 (es) |
CA (1) | CA3041279A1 (es) |
IL (1) | IL266860B1 (es) |
MX (3) | MX2019005756A (es) |
RU (1) | RU2019119206A (es) |
TW (2) | TWI797097B (es) |
WO (1) | WO2018097307A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20181275A1 (es) | 2015-08-28 | 2018-08-03 | Amunix Operating Inc | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo |
WO2018097307A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
SG11202004627WA (en) * | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Ligand-binding molecule having adjustable ligand-binding activity |
US20200369781A1 (en) * | 2017-11-28 | 2020-11-26 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide including antigen-binding domain and carrying section |
WO2019230866A1 (en) * | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
EP3807312A4 (en) * | 2018-05-30 | 2022-07-20 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT |
KR20220017430A (ko) | 2019-06-05 | 2022-02-11 | 추가이 세이야쿠 가부시키가이샤 | 항체 절단 부위 결합 분자 |
CN114127277A (zh) * | 2019-06-05 | 2022-03-01 | 中外制药株式会社 | 蛋白酶底物和包含蛋白酶切割序列的多肽 |
EP4373862A1 (en) | 2021-07-19 | 2024-05-29 | Chugai Seiyaku Kabushiki Kaisha | Protease-mediated target specific cytokine delivery using fusion polypeptide |
CN117031043B (zh) * | 2023-09-28 | 2024-01-02 | 中国中医科学院中药研究所 | 人工虎骨粉检测标志物鉴定方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
JP2005168328A (ja) | 2003-12-08 | 2005-06-30 | Hokkaido Univ | シグナル伝達活性を有する細胞質蛋白質の活性制御方法 |
AU2005244271B2 (en) | 2004-04-12 | 2010-04-08 | Vertex Pharmaceuticals Incorporated | Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
CA2620886C (en) | 2005-08-31 | 2017-03-14 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
EP1938106A1 (en) | 2005-10-20 | 2008-07-02 | Nordic Bioscience A/S | Detection or quantification of aggrecan and its fragments |
US20070099246A1 (en) | 2005-11-03 | 2007-05-03 | Sandy John D | Antibodies, assays and kits to quantitate cartilage destruction |
EP1957536A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
DK2046951T5 (da) | 2006-07-05 | 2012-01-23 | Catalyst Biosciences Inc | Proteasesreeningsmetoder og proteaser identificeret dermed |
DK2049564T3 (en) | 2006-08-02 | 2017-07-24 | Uab Res Found | METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE Lymphocyte RECEPTORS WITH DEFINED ANTIGEN SPECIFICITY |
KR20100018040A (ko) | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
MX2009013816A (es) | 2007-06-21 | 2010-02-24 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos. |
US9624309B2 (en) | 2007-08-15 | 2017-04-18 | Bayer Intellectual Property Gmbh | Monospecific and multispecific antibodies and method of use |
CA2697032C (en) * | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2016213702C1 (en) * | 2007-08-22 | 2018-11-29 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2009143472A2 (en) | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
US20100079580A1 (en) | 2008-09-30 | 2010-04-01 | Waring Iv George O | Apparatus and method for biomedical imaging |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
CN105399828B (zh) * | 2009-04-10 | 2021-01-15 | 埃博灵克斯股份有限公司 | 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽 |
JP2011026294A (ja) | 2009-06-26 | 2011-02-10 | Canon Inc | 化合物 |
SG178443A1 (en) | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | CYTOKINES ACTIVATED BY PROTEASES |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
TW201326209A (zh) * | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
KR20150030639A (ko) | 2012-03-30 | 2015-03-20 | 바이엘 헬스케어 엘엘씨 | 프로테아제로 조절된 항체 |
ES2670668T3 (es) | 2012-04-06 | 2018-05-31 | Omeros Corporation | Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica |
JP6178846B2 (ja) | 2012-05-22 | 2017-08-09 | ライフ テクノロジーズ エーエス | 組み換え抗体組成物およびその使用方法 |
RU2015101803A (ru) | 2012-06-22 | 2016-08-20 | Сайтомкс Терапьютикс, Инк. | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения |
US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
US9850316B2 (en) | 2013-02-15 | 2017-12-26 | National University Corporation Kyoto Institute Of Technology | Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof |
MX2016003957A (es) | 2013-09-25 | 2017-02-02 | Cytomx Therapeutics Inc | Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos. |
US10501737B2 (en) | 2013-09-30 | 2019-12-10 | Chugai Seiyaku Kabushiki Kaisha | Method for producing antigen-binding molecule using modified helper phage |
WO2015066279A2 (en) * | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
US10323083B2 (en) | 2014-01-15 | 2019-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Agents that specifically bind matrilin-3 and their use |
JP6835586B2 (ja) | 2014-01-31 | 2021-02-24 | シトムクス セラピューティクス,インコーポレイティド | マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
MX2016010174A (es) | 2014-02-06 | 2016-11-15 | Hoffmann La Roche | Proteinas de fusion de interleucina-10 y usos de las mismas. |
EP3119194B1 (en) | 2014-03-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
GB201413357D0 (en) | 2014-07-28 | 2014-09-10 | Philogen Spa | Antibodies for treatment and diagnosis |
AU2015323313B2 (en) | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
KR20170083095A (ko) | 2014-11-11 | 2017-07-17 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 표적화된 xten 접합체 조성물 및 이의 제조 방법 |
MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
EP3288981A1 (en) * | 2015-05-01 | 2018-03-07 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
LT3292149T (lt) | 2015-05-04 | 2022-03-10 | Cytomx Therapeutics, Inc. | Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai |
EA201792414A1 (ru) | 2015-05-04 | 2018-06-29 | Сайтомкс Терапьютикс, Инк. | Антитела против cd166, активируемые антитела против cd166 и способы их применения |
EP3292151A1 (en) | 2015-05-04 | 2018-03-14 | Cytomx Therapeutics Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
WO2017025698A1 (en) | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
CR20180453A (es) | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗pd-l1抗体 |
MX2019004775A (es) | 2016-11-03 | 2019-08-05 | Squibb Bristol Myers Co | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos. |
US20200207846A1 (en) | 2016-11-28 | 2020-07-02 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
WO2018097307A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
MX2019006897A (es) | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
KR20200013247A (ko) | 2017-06-02 | 2020-02-06 | 아블린쓰 엔.브이. | 아그레칸 결합 면역글로불린 |
US11813307B2 (en) | 2017-06-02 | 2023-11-14 | Merck Patent Gmbh | Polypeptides binding ADAMTS5, MMP13 and aggrecan |
KR20200037781A (ko) | 2017-07-03 | 2020-04-09 | 토크 테라퓨틱스, 인코포레이티드 | 면역자극 융합 분자 및 이의 용도 |
CN107602706B (zh) | 2017-10-16 | 2020-12-04 | 湖北大学 | 一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用 |
US20200369781A1 (en) | 2017-11-28 | 2020-11-26 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide including antigen-binding domain and carrying section |
SG11202004627WA (en) | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Ligand-binding molecule having adjustable ligand-binding activity |
KR102020131B1 (ko) | 2017-12-29 | 2019-09-09 | 박성원 | 광경화성 조성물 및 이를 이용하여 제조된 성형품 |
JP2021515599A (ja) | 2018-03-09 | 2021-06-24 | アスクジーン・ファーマ・インコーポレイテッドAskGene Pharma, Inc. | 新規のサイトカインプロドラッグ |
JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なインターロイキン-2ポリペプチド及びその使用方法 |
CA3100018A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
EP3807312A4 (en) | 2018-05-30 | 2022-07-20 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT |
US20210253672A1 (en) | 2018-05-30 | 2021-08-19 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule containing single domain antibody |
WO2019230866A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
EP3856764A4 (en) | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
WO2020072821A2 (en) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CN114127277A (zh) * | 2019-06-05 | 2022-03-01 | 中外制药株式会社 | 蛋白酶底物和包含蛋白酶切割序列的多肽 |
CN115943210A (zh) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
-
2017
- 2017-11-28 WO PCT/JP2017/042542 patent/WO2018097307A1/ja active Application Filing
- 2017-11-28 EP EP17873230.1A patent/EP3546574A4/en active Pending
- 2017-11-28 RU RU2019119206A patent/RU2019119206A/ru unknown
- 2017-11-28 JP JP2018553013A patent/JP7001615B2/ja active Active
- 2017-11-28 AU AU2017364817A patent/AU2017364817B2/en active Active
- 2017-11-28 BR BR112019008727A patent/BR112019008727A2/pt unknown
- 2017-11-28 US US16/463,222 patent/US11168139B2/en active Active
- 2017-11-28 MX MX2019005756A patent/MX2019005756A/es unknown
- 2017-11-28 CN CN201780083314.4A patent/CN110177875B/zh active Active
- 2017-11-28 CA CA3041279A patent/CA3041279A1/en active Pending
- 2017-11-28 TW TW106141342A patent/TWI797097B/zh active
- 2017-11-28 CN CN202311627832.1A patent/CN117630386A/zh active Pending
- 2017-11-28 TW TW112106655A patent/TW202323287A/zh unknown
- 2017-11-28 IL IL266860A patent/IL266860B1/en unknown
- 2017-11-28 KR KR1020197017805A patent/KR102630923B1/ko active IP Right Grant
- 2017-11-28 KR KR1020247002814A patent/KR20240018673A/ko not_active Application Discontinuation
-
2019
- 2019-05-16 MX MX2023010419A patent/MX2023010419A/es unknown
- 2019-05-16 MX MX2023010418A patent/MX2023010418A/es unknown
-
2021
- 2021-09-17 US US17/477,983 patent/US11932697B2/en active Active
- 2021-12-24 JP JP2021210053A patent/JP7432575B2/ja active Active
-
2023
- 2023-11-10 JP JP2023191990A patent/JP2023184746A/ja active Pending
- 2023-12-22 US US18/393,918 patent/US20240150476A1/en active Pending
-
2024
- 2024-01-18 AU AU2024200345A patent/AU2024200345A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023010418A (es) | Dominio de union al antigeno y polipeptido que incluye seccion de transporte. | |
MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
SG10201901057UA (en) | Anti-pd-l1 antibodies | |
CL2019000325A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de piridona policiclico sustituido o su sal, que tiene actividad inhibidora de la endonucleasa dependiente de cap; cristal; y composicion farmaceutica que comprende dicho cristal. | |
MX2019002946A (es) | Anticuerpos anti-pd-1 y sus usos. | |
NZ728688A (en) | Anti-pd-1 antibodies | |
MX2016007887A (es) | Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2. | |
EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
PH12017502161A1 (en) | Anti-cd40 antibodies and uses thereof | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
EP3505535A4 (en) | MONOCLONAL ANTI-PD-1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | |
SG10201902813XA (en) | Methods and materials for biosynthesis of mogroside compounds | |
SG10201811816RA (en) | Chimeric antigen receptors and methods of making | |
MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
EP3459973A4 (en) | HUMANIZED MONOCLONAL ANTI-HUMAN PD-L1 ANTIBODY AND APPLICATION THEREOF | |
EP3261663A4 (en) | Crystals of anti-human pd-1 monoclonal antibodies | |
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
BR112016025056A2 (pt) | uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica | |
HK1250937A1 (zh) | 穩定的包含cd147單克隆抗體的藥物製劑 | |
CR20210200A (es) | Formulación de anticuerpos | |
NZ728981A (en) | Anti-ceramide antibodies | |
MX2018007520A (es) | Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano. | |
EP3432925A4 (en) | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. |